Mereo BioPharma Group plc has finalized an agreement that could Yield $40 million in upfront payments and up to $435 million in milestone payments for the rights to alvelestat, a treatment for AATD-LD. This vital Partnership marks an essential step towards capitalizing on a new market opportunity, enhancing Mereo's financial prospects.
Key Highlights
- Mereo BioPharma can earn up to $435 million in milestone payments under the agreement.
- Mereo BioPharma secured a $40 million upfront payment from Sentynl Therapeutics for alvelestat rights.
- The collaboration includes potential milestone payments that could exceed $435 million.
- Mereo’s share price has risen 7.6 % over the past month following the agreement.
$40M Upfront Option Secured
Mereo BioPharma Group plc (NASDAQ: MREO) secured a landmark agreement offering a $40 million upfront payment in collaboration with Sentynl Therapeutics for the rights to alvelestat. This agreement also includes potential milestones exceeding $435 million, directly linking Mereo’s strategic direction in rare disease therapy development to broader market opportunities.
Strategic Collaboration with Sentynl
The collaboration with Sentynl, which is focused on rare diseases, aims to refine the Phase 3 study design and advance Manufacturing processes for alvelestat. This partnership could position Mereo to become a key player in treating a condition that currently lacks effective oral therapies. The potential for high milestone payments also creates an optimistic outlook for the firm’s financial health.
Current Market Position
Mereo’s share price, which has risen 7.6% over the past month, reflects growing investor interest following this agreement. The stock's abrupt rise may suggest renewed confidence among investors, particularly as Mereo's strategic investments in alvelestat become clearer. However, the stock remains significantly down year-to-date, indicating potential Volatility as investors weigh the implications of the partnership.
Future Developments to Monitor
Mereo's next quarterly report, due on September 30, 2026, will be important in evaluating the impact of the Sentynl agreement on its operational and financial outlook. This report will likely include insights into interim results from ongoing Clinical Trials and a detailed plan for advancing alvelestat into Phase 3. With the collaboration expected to deliver tangible outcomes, the market will be closely watching how Mereo navigates this key partnership and its implications for future Earnings as the company expands its pipeline to include this promising therapy.
Peers Moving on This News
- Barinthus Biotherapeutics PLC (NASDAQ: BRNS) up 4.8%
- Roivant Sciences Ltd (NASDAQ: ROIV) down 1.1%



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...